A combined fracture and mortality risk index useful for treatment stratification in hip fragility fractures

Erdem Aras Sezgin, Ahmet Toygun Tor, Vėtra Markevičiūtė, Aurimas Širka, Šarūnas Tarasevičius, Deepak Bushan Raina, Yang Liu, Hanna Isaksson, Magnus Tägil, Lars Lidgren, Erdem Aras Sezgin, Ahmet Toygun Tor, Vėtra Markevičiūtė, Aurimas Širka, Šarūnas Tarasevičius, Deepak Bushan Raina, Yang Liu, Hanna Isaksson, Magnus Tägil, Lars Lidgren

Abstract

Objectives: In this study, we aimed to assess the stratification ability of the Fracture and Mortality Risk Evaluation (FAME) index for reoperation, new fragility fracture, and mortality during one-year follow-up.

Patients and methods: Between November 2018 and July 2019, a total of 94 consecutive hip fragility fracture patients from two centers (20 males, 74 females; mean age: 79.3±8.9 years; range, 57 to 100 years) were retrospectively analyzed. The patients were classified into high, intermediate, and low fracture and mortality risk groups according to the Fracture Risk Assessment Tool (FRAX) score and Sernbo score, respectively, as well as nine combined categories according to the FAME index. Hospital records were reviewed to identify re-fractures (reoperations, implant failure, new fragility fractures on any site) and mortality at one year following the FAME index classification.

Results: Overall re-fracture and mortality rates were 20.2% and 33%, respectively. High fracture risk category (FRAX-H) was significantly associated with higher re-fracture (odds ratio [OR]: 2.9, 95% confidence interval [CI]: 1-8.2, p=0.037) and mortality rates compared to others (OR: 3.7, 95% CI: 1.5-9.3, p=0.003). The patients classified within the FRAX-H category (n=35) had different mortality rates according to their Sernbo classification; i.e., patients classified as low mortality risk (Sernbo-L) (n=17) had lower mortality rates compared to others in this group (n=18) (35.3% and 66.7%, respectively), indicating a low statistical significance (OR: 0.3, 95% CI: 0.1-1.1, p=0.063). Similarly, within patients classified in Sernbo-L category (n=64), those classified as high fracture risk (FRAX-H) (n=17) had significantly higher re-fracture rates compared to others in this group (n=47) (35.3% and 8.5%, respectively), (OR: 5.9; 95% CI: 1.4-24.5), (p=0.017). Multivariate logistic regression analyses adjusting for covariates (age, sex, length of hospital stay and BMI) yielded similar results.

Conclusion: The FAME index appears to be a useful stratification tool for allocating patients in a randomized-controlled trial for augmentation of hip fragility fractures.

Conflict of interest statement

Conflict of Interest: LL is a board member of Bone Support AB, Lund, Sweden and Ortho Cell, Australia. The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

References

    1. Metcalfe D, Judge A, Perry DC, Gabbe B, Zogg CK, Costa ML. Total hip arthroplasty versus hemiarthroplasty for independently mobile older adults with intracapsular hip fractures. BMC Musculoskelet Disord. 2019;20:226–226.
    1. Zhao Y, Fu D, Chen K, Li G, Cai Z, Shi Y, et al. Outcome of hemiarthroplasty and total hip replacement for active elderly patients with displaced femoral neck fractures: a meta-analysis of 8 randomized clinical trials. e98071PLoS One. 2014;9
    1. Nherera L, Trueman P, Horner A, Watson T, Johnstone AJ. Comparison of a twin interlocking derotation and compression screw cephalomedullary nail (InterTAN) with a single screw derotation cephalomedullary nail (proximal femoral nail antirotation): a systematic review and metaanalysis for intertrochanteric fractures. J Orthop Surg Res. 2018;13:46–46.
    1. Selim A, Ponugoti N, Naqvi AZ, Magill H. Cephalomedullary nailing versus dynamic hip screw with trochanteric stabilisation plate for the treatment of unstable per-trochanteric hip fractures: A meta-analysis. J Orthop Surg Res. 2021;16:47–47.
    1. Smith L, Albersheim M, Blaschke BL, Parikh HR, Solfelt DA, Van Heest AE, et al. Trend and economic implications of implant selection in the treatment of intertrochanteric hip fractures: A review of the American Board of Orthopaedic Surgery Database From 2007 to 2017. J Am Acad Orthop Surg. 2021;29:789–795.
    1. Ekinci Y, Gürbüz K, Batın S, Kahraman M, Doğar F, Kaya Erten Z. A multicenter intertrochanteric fracture study in the elderly: Hemiarthroplasty versus proximal femoral nailing. Jt Dis Relat Surg. 2020;31:209–217.
    1. Bergström U, Jonsson H, Gustafson Y, Pettersson U, Stenlund H, Svensson O. The hip fracture incidence curve is shifting to the right. Acta Orthop. 2009;80:520–524.
    1. Williamson S, Landeiro F, McConnell T, Fulford-Smith L, Javaid MK, Judge A, et al. Costs of fragility hip fractures globally: A systematic review and meta-regression analysis. Osteoporos Int. 2017;28:2791–2800.
    1. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos. 2013;8:136–136.
    1. Dreinhöfer KE, Mitchell PJ, Bégué T, Cooper C, Costa ML, Falaschi P, et al. A global call to action to improve the care of people with fragility fractures. Injury. 2018;49:1393–1397.
    1. Morochovič R, Kňazovický M, Paulo M, Takáčová K, Burda R. Reversed Z-effect and Z-effect phenomena in femoral neck fracture treated with a dynamic locking plate fixation: Case report. Jt Dis Relat Surg. 2021;32:249–252.
    1. Goodnough LH, Wadhwa H, Tigchelaar SS, DeBaun MR, Chen MJ, Graves ML, et al. Indications for cement augmentation in fixation of geriatric intertrochanteric femur fractures: A systematic review of evidence. Arch Orthop Trauma Surg. 2021
    1. Heini PF, Franz T, Fankhauser C, Gasser B, Ganz R. Femoroplasty-augmentation of mechanical properties in the osteoporotic proximal femur: A biomechanical investigation of PMMA reinforcement in cadaver bones. Clin Biomech (Bristol, Avon) 2004;19:506–512.
    1. Kok J, Širka A, Grassi L, Raina DB, Tarasevičius Š, Tägil M, et al. Fracture strength of the proximal femur injected with a calcium sulfate/hydroxyapatite bone substitute. Clin Biomech (Bristol, Avon) 2019;63:172–178.
    1. Kok J, Širka A, Liu Y, Tarasevičius Š, Belickas J, Tägil M, et al. Augmenting a dynamic hip screw with a calcium sulfate/ hydroxyapatite biomaterial. Med Eng Phys. 2021;92:102–109.
    1. Širka A, Raina DB, Isaksson H, Tanner KE, Smailys A, Kumar A, et al. Calcium sulphate/hydroxyapatite carrier for bone formation in the femoral neck of osteoporotic rats. Tissue Eng Part A. 2018;24:1753–1764.
    1. Kammerlander C, Neuerburg C, Verlaan JJ, Schmoelz W, Miclau T, Larsson S. The use of augmentation techniques in osteoporotic fracture fixation. S36-43Injury. 2016;47 Suppl 2
    1. Mattsson P, Alberts A, Dahlberg G, Sohlman M, Hyldahl HC, Larsson S. Resorbable cement for the augmentation of internally-fixed unstable trochanteric fractures. A prospective, randomised multicentre study. J Bone Joint Surg [Br] 2005;87:1203–1209.
    1. Kim SJ, Park HS, Lee DW, Lee JW. Is calcium phosphate augmentation a viable option for osteoporotic hip fractures. Osteoporos Int. 2018;29:2021–2028.
    1. Sezgin EA, Markevičiūtė V, Širka A, Tarasevičius Š, Raina DB, Isaksson H, et al. Combined fracture and mortality risk evaluation for stratifying treatment in hip fracture patients: A feasibility study. Jt Dis Relat Surg. 2020;31:163–168.
    1. Mellner C, Eisler T, Börsbo J, Brodén C, Morberg P, Mukka S. The Sernbo score predicts 1-year mortality after displaced femoral neck fractures treated with a hip arthroplasty. Acta Orthop. 2017;88:402–406.
    1. Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12:43–43.
    1. Mellner C, Hedström M, Hommel A, Sköldenberg O, Eisler T, Mukka S. The Sernbo score as a predictor of 1-year mortality after hip fracture: a registry study on 55,716 patients. Eur J Trauma Emerg Surg. 2020 [Online ahead of print]
    1. Roux C, Thomas T, Paccou J, Bizouard G, Crochard A, Toth E, et al. Refracture and mortality following hospitalization for severe osteoporotic fractures: The Fractos Study. e10507JBMR Plus. 2021;5
    1. Bliuc D, Nguyen ND, Nguyen TV, Eisman JA, Center JR. Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. J Bone Miner Res. 2013;28:2317–2324.
    1. Stravinskas M, Tarasevicius S, Laukaitis S, Nilsson M, Raina DB, Lidgren L. A ceramic bone substitute containing gentamicin gives good outcome in trochanteric hip fractures treated with dynamic hip screw and in revision of total hip arthroplasty: A case series. BMC Musculoskelet Disord. 2018;19:438–438.
    1. Raina DB, Larsson D, Sezgin EA, Isaksson H, Tägil M, Lidgren L. Biomodulation of an implant for enhanced boneimplant anchorage. Acta Biomater. 2019;96:619–630.
    1. Raina DB, Širka A, Qayoom I, Teotia AK, Liu Y, Tarasevicius S, et al. Long-term response to a bioactive biphasic biomaterial in the femoral neck of osteoporotic Rats. Tissue Eng Part A. 2020;26:1042–1051.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever